Bioprosthetic Aortic Valves: FDA Notification - Reduced Leaflet Motion

FDA is working to design clinical studies to fully evaluate reduced valve leaflet motion. At this time, FDA believes that bioprosthetic aortic valves remain reasonably safe and effective when used according to their approved indications.

 
comments powered by Disqus